On Sept 26, Frequency Therapeutics Gave Notice To Oppenheimer Of Termination Of Sales Deal Pursuant To Section 11(B) Thereof, Effective Immediately; Is Not Subject To Any Termination Penalties Related To Termination Of Sales Agreement
Portfolio Pulse from Benzinga Newsdesk
Frequency Therapeutics has terminated its sales agreement with Oppenheimer, effective immediately, according to an SEC filing. The termination is not subject to any penalties.
September 27, 2023 | 8:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Frequency Therapeutics has ended its sales agreement with Oppenheimer. This could potentially impact the company's sales and revenue streams.
The termination of the sales agreement with Oppenheimer could potentially disrupt Frequency Therapeutics' sales and revenue streams in the short term. However, the absence of termination penalties minimizes financial loss.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100